Last reviewed · How we verify

docetaxel - cisplatin - 5-fluorouracil

Gruppo Oncologico del Nord-Ovest · Phase 3 active Small molecule

docetaxel - cisplatin - 5-fluorouracil is a Taxane and platinum-based chemotherapy Small molecule drug developed by Gruppo Oncologico del Nord-Ovest. It is currently in Phase 3 development for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.

Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, and 5-fluorouracil inhibits thymidylate synthase.

Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, and 5-fluorouracil inhibits thymidylate synthase. Used for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.

At a glance

Generic namedocetaxel - cisplatin - 5-fluorouracil
SponsorGruppo Oncologico del Nord-Ovest
Drug classTaxane and platinum-based chemotherapy
TargetMicrotubules and DNA
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Docetaxel binds to tubulin, preventing microtubule polymerization and cell division. Cisplatin forms platinum-DNA adducts, causing DNA damage and apoptosis. 5-Fluorouracil is converted to its active metabolite, which inhibits thymidylate synthase, leading to DNA synthesis inhibition and cell death.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about docetaxel - cisplatin - 5-fluorouracil

What is docetaxel - cisplatin - 5-fluorouracil?

docetaxel - cisplatin - 5-fluorouracil is a Taxane and platinum-based chemotherapy drug developed by Gruppo Oncologico del Nord-Ovest, indicated for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.

How does docetaxel - cisplatin - 5-fluorouracil work?

Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, and 5-fluorouracil inhibits thymidylate synthase.

What is docetaxel - cisplatin - 5-fluorouracil used for?

docetaxel - cisplatin - 5-fluorouracil is indicated for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.

Who makes docetaxel - cisplatin - 5-fluorouracil?

docetaxel - cisplatin - 5-fluorouracil is developed by Gruppo Oncologico del Nord-Ovest (see full Gruppo Oncologico del Nord-Ovest pipeline at /company/gruppo-oncologico-del-nord-ovest).

What drug class is docetaxel - cisplatin - 5-fluorouracil in?

docetaxel - cisplatin - 5-fluorouracil belongs to the Taxane and platinum-based chemotherapy class. See all Taxane and platinum-based chemotherapy drugs at /class/taxane-and-platinum-based-chemotherapy.

What development phase is docetaxel - cisplatin - 5-fluorouracil in?

docetaxel - cisplatin - 5-fluorouracil is in Phase 3.

What are the side effects of docetaxel - cisplatin - 5-fluorouracil?

Common side effects of docetaxel - cisplatin - 5-fluorouracil include Neutropenia, Anemia, Thrombocytopenia, Nausea and vomiting, Diarrhea, Fatigue.

What does docetaxel - cisplatin - 5-fluorouracil target?

docetaxel - cisplatin - 5-fluorouracil targets Microtubules and DNA and is a Taxane and platinum-based chemotherapy.

Related